Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
So is this a good stock then?
Moral of the story.
Stop giving reverse split machines your money. Learn to actually trade the market where stocks aren't lotto tickets.
Seeing sub-human trash scam artists pump this POS only days before the reverse split-merger into a company that's the bio equivalent of DRYS hurts my soul.
GALE,NOW=TRADING-AS-SLS/POST-SPLIT:CEO COMPENSATION=OF INTEREST to shareholders who got scre#ed as always in the dilution of their value:
the entire prev. Board & Management of Galena resigned upon this change, but they wanted to make sure new CEO is taken care of:
Only hope is he affects sale/merger but so far these changes have been detrimental to shareholder value, just keeping the lights on somehow:
someone will write Galena's story as legalized mafia-style theft from the public under the SEC's nose: is this the worst-performing stock ever? Not long ago it was ranked among the 5 worst, anyway:
https://globenewswire.com/news-release/2017/12/29/1276660/0/en/Galena-Biopharma-Inc-Stockholders-Approve-Business-Combination-with-SELLAS-Life-Sciences-Group-Ltd-Board-Sets-Reverse-Stock-Split-Ratio.html
Angelos M. Stergiou, M.D., Sc.D. h.c.
In September 2016, Private SELLAS entered into an employment agreement with Dr. Stergiou, the Registrant's newly appointed chief executive officer, which continues to govern Dr. Stergiou's employment with the Registrant following the Merger. Under this employment agreement, Dr. Stergiou is entitled to an annual base salary of $400,000 (subject to review and adjustment in the discretion of the board of directors or its compensation committee) and a discretionary annual cash bonus, with a target amount no less than 30% of Dr. Stergiou's then
effective base salary (subject to continued employment and the achievement of certain performance objectives established by the employer's board of directors or compensation committee). This employment agreement also provides that Dr. Stergiou will receive a monthly housing allowance of $10,000 and may be eligible to receive an additional discretionary bonus as determined by the employer in its sole discretion.
Dr. Stergiou's employment agreement also provides for additional bonuses in the event of an initial public offering ("IPO") or trade sale by Private SELLAS, in each case that meets certain terms. The Merger is not considered an IPO or trade sale for purposes of Dr. Stergiou's employment agreement, and Dr. Stergiou is not eligible to receive the IPO bonuses or a trade sale bonus in connection with the Merger.
In connection with Dr. Stergiou entering into his employment agreement, and pursuant to the terms thereof, Private SELLAS issued to Dr. Stergiou 827 Private SELLAS restricted stock units ("RSUs") on November 22, 2016. Dr. Stergiou's Private SELLAS RSUs were scheduled to vest on November 22, 2017 and were subject to accelerated vesting upon a change in control of Private SELLAS and certain terminations of employment; however, on August 7, 2017, the board of directors accelerated the vesting of such Private SELLAS RSUs in full and Private SELLAS shares were issued to Dr. Stergiou upon settlement of the Private SELLAS RSUs.
Dr. Stergiou's employment agreement does not have a specified term and either party may terminate Dr. Stergiou's employment agreement by providing written notice at any time, with or without cause. If the employer terminates Dr. Stergiou's employment without cause or Dr. Stergiou resigns for good reason, Dr. Stergiou will be eligible to receive a lump-sum payment equal to two years of his annual base salary. In addition, if such termination or resignation occurs within one month prior to or twelve months following a change in control, Dr. Stergiou will be eligible to receive full vesting of his then outstanding stock awards and any options held by Dr. Stergiou may be exercised during the 12 month period following termination, or if earlier, the expiration date of the options. The employer must provide Dr. Stergiou with six months' notice prior to a termination without cause and may elect to place Dr. Stergiou on garden leave (with base salary and other benefits) during such period. Upon termination of his employment due to death or disability, Dr. Stergiou is eligible for a pro-rated bonus for the year in which terminated.
DD you been around. I have been in this little POS awhile.
They R/S on my good amount back a bit. Now a 30-1 rs split
All I have left is 50 shares, LOL does this mean all I got is @ 1.75 share at a cost average of $199 lol.
Let us know the next stock you buy so we can run far away.
* * $GALE Video Chart 12-29-17 * *
Link to Video - click here to watch the technical chart video
wahhhhhhhhhhhh
GALE stock price will be 3000% higher!!!
I am all in.
Next run will be huge, no resistance on level 2 IMO its going back to .35 or .36
There will be another run today......
GALE becomes SLS 1/2/18—following 1:30 reverse split after the close today:
https://globenewswire.com/news-release/2017/12/29/1276660/0/en/Galena-Biopharma-Inc-Stockholders-Approve-Business-Combination-with-SELLAS-Life-Sciences-Group-Ltd-Board-Sets-Reverse-Stock-Split-Ratio.html
This reverse merger was announced in Aug 2017 (#msg-133668985).
Actually, a reverse split concurrent with the closing of a reverse merger is quite common.
RS is weird here because of the RM so mucho risko lol but we'll see how this plays out. A good "gamble" to make Friday and next week exciting (I'm not putting a lot in here just free money I got from SANP a fee weeks ago)
so shorts must cover today or loose it all
Same buddy - current technicals indicate it won't get into overbought territory until .90s keeping with this momentum.
GLTU - I am hoping for $1+ soon.
Bought in more this morning at .38 I know might seem high but I am hoping for a massive momentum here this week coming up.
Galena Biopharma to effect the reverse stock split of the Galena common stock at a ratio of 1for-30; reverse stock split is expected to become effective at 4:15 p.m. ET today, December 29, 2017 GALE
Briefing.com
shorts gettin their due,lol $$$$$$$$$$$$
GALE IS MOVING ON MERGER NEWS
Galena Biopharma has a consensus price target of $4.00, suggesting a potential upside of 1,328.57%
I have not read much of the proposed votes but why don't shareholders like the SELLAS merger deal? Seems like a good opportunity for the company moving forward.
Lol! Only us that got stuck when phase III was shut down. I was on vacation at at the time and thought it was a no brainer. One lesson I learned is that it is all about management(or lack there of).
They still have shareholders?
Management must not be seeing the voting going the way that they want. Delayed until Dec 29th. How many more phone calls will I get from McMillan?
Merger good for GALE holders?
Totally serious. I know of only one other shareholder voting yes. Management has never done anything for longtime shareholders, hence no votes on all items,
I thought you were serious for a second there. That was pretty funny.
I believe most shareholders have already voted no on all items.
Galena Biopharma Reminds Shareholders to Vote Ahead of Special Meeting on December 15, 2017
SELLAS Life Sciences Group Ltd (“SELLAS”) will be combined (the “Merger”).
I remember the title of a post on here about a year ago, the title was...
"Reasons why I am confident in my GALE investment"
I think back on that post and laugh, because that new and over confident investor went bankrupt and made himself look like a fool in front of everyone...
Anytime someone is cocky and arrogant and they fail, I guess they get what they deserve.
Confidence is a good quality, but smug arrogance results in, bankruptcy, unemployment, divorce, prison and a good old fashioned @ss-kicking.
I hope that young idiot learned to not be so arrogant and to diversify and to not go all in...
MGT cant get the votes for MERG.=We may get a better deal?
Don't be a seller be a SELLAS
I remember what happened with BPAX becoming ANIP and OPXA becoming ACER recently. Holding shares and options in GALE and hopefully SELLAS soon.
Q= Did SELLAS walk away from this JUNK??
Why is human trash still trying to pump this pos?
It's over. It was over the moment I wrote the big, fat HALT FOR FUTILITY AT INTERIM at the top of the page.
Find some other piece of shit to manipulate.
never ever happen to this pos company, hopefully it get delisted an the end comes. no more stealing money from investors an putting it in their pockets. sec needs to delist gale, they have our vote! junk!
Impressive list of Institutional-Holders,yet PPS=stagnant,IS there hope after all? IMO after the last June disappointment on top of all the management scandals they're running out of time to really hit one out of the park, a triple home run like the Dodgers just had e.g.:
They need something that actually cures or at least significantly impedes growth/spread of cancer and/or other deadly disease:
Is that too much to ask of a company that's devoted billions and lost blllions of investor money in that very cause?
Galena Biopharma Inc, Inst Holders, 3Q 2017 (GALE)
1 day 15 hours 47 minutes ago - DJNF
The following table shows the largest shareholders in GALENA BIOPHARMA INC COM (GALE) for the quarter ended September 30, 2017, listed by holding size. The list represents up to 50 of the largest holders in the company.
Note: Unless otherwise mentioned the reporting date is 09/30/2017
Institution Shares Shares % Last
Held Changed Held Report
Sabby Capital LLC 2,644,522 178,662 6.886 06/30
Renaissance Technologies LLC 2,221,086 620,811 5.783 06/30
KCG Americas LLC 224,050 195,230 0.583 06/30
Element Capital Management LLC 160,238 160,238 0.417 06/30
Goldman Sachs & Co. LLC (Priva 131,604 (82,477) 0.343 06/30
BlackRock Fund Advisors 131,434 (481,678) 0.342 06/30
Ergoteles LLC 120,800 120,800 0.315 06/30
SSgA Funds Management Inc. 114,431 (145,494) 0.298 06/30
Millennium Management LLC 111,996 (196,910) 0.292 06/30
Crescent Grove Advisors LLC 100,000 100,000 0.260 06/30
Citadel Advisors LLC 93,273 (69,304) 0.243 06/30
Morgan Stanley & Co. LLC 67,529 7,407 0.176 06/30
LMR Partners LLP 58,023 58,023 0.151 06/30
Geode Capital Management LLC 51,783 (50,915) 0.135 06/30
DAFNA Capital Management LLC 46,145 0 0.120 06/30
Northern Trust Investments In 39,908 (88,862) 0.104 06/30
Tower Research Capital LLC 35,078 (20,871) 0.091 06/30
D. E. Shaw & Co. LP 23,733 23,733 0.062 06/30
The California Public Employee 23,582 0 0.061 06/30
Squarepoint OPS LLC 20,942 20,942 0.055 06/30
Susquehanna Financial Group LL 19,946 (1,552) 0.052 06/30
Wells Fargo Advisors Financial 19,682 0 0.051 06/30
Mariner Wealth Advisors LLC 15,150 15,150 0.039 03/31
Morgan Stanley Smith Barney LL 13,739 0 0.036 06/30
David Vaughan Investments Inc 13,002 0 0.034 06/30
Guggenheim Funds Investment Ad 12,776 0 0.033 06/30
The Bank of New York Mellon Co 8,590 (17,451) 0.022 06/30
Citigroup Global Markets Inc. 7,041 1,941 0.018 06/30
BNY Mellon Capital Markets LLC 5,459 (6,289) 0.014 06/30
Spot Trading LLC 5,000 0 0.013 06/30
Vanguard Fiduciary Trust Co. 4,690 (54,778) 0.012 06/30
Winfield Associates Inc. 3,000 0 0.008 06/30
Meeder Asset Management Inc. 1,989 508 0.005 06/30
BlackRock Advisors LLC 1,385 (3,917) 0.004 06/30
Simplex Trading LLC 1,000 1,000 0.003 06/30
Royal Alliance Associates Inc 747 (3) 0.002 06/30
Triad Hybrid Solutions LLC 740 0 0.002 06/30
Wells Fargo Clearing Services 700 0 0.002 06/30
Pittenger & Anderson Inc. 400 400 0.001 06/30
Securities America Advisors I 387 (250) 0.001 06/30
UBS Securities LLC 351 (22,095) 0.001 06/30
Springbok Capital Management L 300 (7,500) 0.001 06/30
Manulife Asset Management Ltd. 248 (26) 0.001 06/30
Valley National Advisers Inc. 128 0 0.000 06/30
IFP Advisors Inc. 112 0 0.000 06/30
San Francisco Sentry Investmen 100 100 0.000 06/30
RBC Dominion Securities Inc. 91 90 0.000 06/30
Deutsche Asset Management Inve 84 (88,645) 0.000 06/30
CWM LLC 25 0 0.000 09/30
NEXT Financial Group Inc. 25 25 0.000 06/30
13F data provided by: Factset Research Systems Inc.;
Please send questions to ownership@factset.com.
Copyright, Factset Research Systems, 2017. All Rights Reserved.
(END) Dow Jones Newswires
They have until March 2018 to come up with a miracle without having to do another confidence-destroying R/S, and they'd better stay away from their infamous Public Offerings Below Current Stock Price:
these investors are a show of confidence, they don't buy to short:
On September 21, 2017, The Nasdaq Stock Market ("Nasdaq") notified Galena Biopharma, Inc. (the "Company") that, while the Company had not regained compliance with the minimum bid price requirement, it was eligible for an additional 180-day grace period, or until March 19, 2018, to regain compliance with the $1.00 per share minimum bid price requirement.
October 20, 2017 03:03 ET (07:03 GMT)
yes indeed, gale failed once again as usual.
You forget to add the C (POSC) TICKER
ANAB has some anti inflammatory suc ess
Seeing that approximately ten percent of shares are currently held short with about twelve days to cover, I'd say it deserves, at best, extremely high risk reward ass essment...
Followers
|
185
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
10489
|
Created
|
03/13/08
|
Type
|
Free
|
Moderators |
SAN RAMON, Calif., April 19, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs, today announced that data from the booster phase of the Company’s GALE-301/GALE-302 Phase 1/2a clinical trial was presented at the American Association for Cancer Research (AACR) Annual Meeting.
The poster, entitled, “Comparing an attenuated booster (E39’) vs. E39 booster to potentiate the clinical benefit of the folate binding protein (FBP)-derived vaccine (E39 + GM-CSF) in a phase I/IIa trial to prevent recurrence in endometrial (EC) and ovarian cancer (OC) patients,” was presented today by Dr. Doreen Jackson from the San Antonio Military Medical Center. In the Phase 2a portion of the trial, patients were randomized to two different boosters: E39 (GALE-301), versus E39’ (GALE-302). The purpose of the study was to evaluate the immune responses and determine which booster, if either, would provide a sustained immune response and potentially longer disease free survival (DFS) rates.
The use of the wildtype peptide (GALE-301/E39) demonstrated the same tolerable safety profile as the attenuated peptide (GALE-302/E39’) with only Grade 1 local reactions and minimal Grade 2 toxicities. Importantly, the percentage of patients who received two booster inoculations and remained disease free was significantly better in the drug treatment arm, versus the control arm (p=0.02), regardless of which booster was used. At median follow up of 16 months, the boosters demonstrated equivalent efficacy after two booster inoculations with an estimated, two-year DFS rate of 66.7% (GALE-301 n=7, GALE-302 n=7) in each booster arm versus 36% (n=22) in the control arm.
“In our GALE-301 Phase 2a trial, we randomized patients to determine an optimal boosting strategy and to see if there was an observable difference between boosting patients with GALE-301 versus the attenuated version of the peptide, GALE-302,” stated Bijan Nejadnik, M.D., Executive Vice President and Chief Medical Officer. “The results show that both boosters were effective with no measurable difference between them, and we will consider this as we continue to evaluate the best path forward for our compounds targeting FBP. The primary analysis of this trial will be presented at the upcoming American Society of Clinical Oncology meeting in June.”
A total of 51 patients were enrolled in the Phase 1/2a trial with 29 HLA-A2-positive patients in the vaccine group (VG) and 22 HLA-A2-negative patients in the control group (CG). Six monthly intradermal inoculations of GALE-301 plus 250mcg GM-CSF were administered to the VG to complete the primary vaccine series (PVS). Patients were then randomized to receive two booster inoculations of 500mcg of GALE-301 or GALE-302 plus 250mcg GM-CSF at six and twelve months post-PVS. Seventeen patients continued onto the booster series and were randomized with 14 receiving two boosters. There were no significant demographic or baseline differences between groups, no difference in toxicities were observed, and there were no Grade 3 or 4 toxicities in either group.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |